secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2021-08-19T23:59:59+00:00
Accession:  0001493152-21-020615
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics delays PT00114 trial start to Jan 2022; Q2 net loss $2.6M
--------------------------------------------------------------------------------

- FDA required ready-to-inject vials; IND re-filing moved to Q4 2021, Phase I/IIa start to Jan 2022.
- Q2 2021 net loss $2.6M (vs $0.6M in Q2 2020); G&A expense rose to $2.2M.
- Closed $13.2M public offering of 3.18M units at $4.15/unit; cash $11.9M as of June 30, 2021.
- Initial Phase I/IIa data readout expected 1H 2022, final readout Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315221020615/0001493152-21-020615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315221020615/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-020615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer